Ghent, Belgium: April 27 2014 - Fujirebio Europe announces the launch of its ProGRP assay to be used on the LUMIPULSE® G1200 chemiluminescent enzyme immunoassay (CLEIA) analyzer. The test is designed for the quantitative determination of ProGRP in human serum or plasma.
Lung cancer can be divided in two subtypes: Small and Non Small Cell Lung Cancers (SCLC & NSCLC). Smoking is a major concern for public health and remains the main cause for the development of SCLC.
“Lung cancer is the leading cancer worldwide today comprising 12.9% of the total new cancer cases and 19.4% of the total cancer deaths according to the International Agency for Research on Cancer.” says Christiaan De Wilde, CEO of Fujirebio Europe. “As the gold standard manufacturer of cancer biomarker assays worldwide we have used our extensive in-house expertise to produce this new ProGRP marker. It will bring value for differential diagnosis between Small Cell and Non Small Cell Lung Cancer. Moreover, ProGRP is the most sensitive assay for SCLC among the whole lung cancer marker range. It is also recommended by the NACB for post-operative surveillance, monitoring therapy and for early detection of recurrence.”
The Lumipulse® G ProGRP assay is a significant addition to the lung cancer test panel already available on the LUMIPULSE® G1200 system: CEA, CYFRA and KL-6 (Krebs von den Lungen). EIA lung cancer markers (SCC and NSE) are also available from Fujirebio.
This product is not available in the USA and in Canada.
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.
The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.
Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.